Nivolumab in Patients With Relapsed or Refractory Hematologic Malignancy: Preliminary Results of a Phase Ib Study

PURPOSE: Cancer cells can exploit the programmed death-1 (PD-1) immune checkpoint pathway to avoid immune surveillance by modulating T-lymphocyte activity. In part, this may occur through overexpression of PD-1 and PD-1 pathway ligands (PD-L1 and PD-L2) in the tumor microenvironment. PD-1 blockade h...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Publicado no:J Clin Oncol
Main Authors: Lesokhin, Alexander M., Ansell, Stephen M., Armand, Philippe, Scott, Emma C., Halwani, Ahmad, Gutierrez, Martin, Millenson, Michael M., Cohen, Adam D., Schuster, Stephen J., Lebovic, Daniel, Dhodapkar, Madhav, Avigan, David, Chapuy, Bjoern, Ligon, Azra H., Freeman, Gordon J., Rodig, Scott J., Cattry, Deepika, Zhu, Lili, Grosso, Joseph F., Bradley Garelik, M. Brigid, Shipp, Margaret A., Borrello, Ivan, Timmerman, John
Formato: Artigo
Idioma:Inglês
Publicado em: American Society of Clinical Oncology 2016
Assuntos:
ORIGINAL REPORTS
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC5019749/
https://ncbi.nlm.nih.gov/pubmed/27269947
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1200/JCO.2015.65.9789
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados